Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Operations: 2018-2024

Historic Cash from Operations for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to -$2.2 million.

  • Fulcrum Therapeutics' Cash from Operations rose 25.60% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.0 million, marking a year-over-year decrease of 596.78%. This contributed to the annual value of -$2.2 million for FY2024, which is 97.56% up from last year.
  • Fulcrum Therapeutics' Cash from Operations amounted to -$2.2 million in FY2024, which was up 97.56% from -$91.0 million recorded in FY2023.
  • Fulcrum Therapeutics' 5-year Cash from Operations high stood at -$2.2 million for FY2024, and its period low was -$97.0 million during FY2022.
  • Over the past 3 years, Fulcrum Therapeutics' median Cash from Operations value was -$91.0 million (recorded in 2023), while the average stood at -$63.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 46.26% in 2021, then skyrocketed by 97.56% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Cash from Operations (Yearly) stood at -$53.7 million in 2020, then slumped by 46.26% to -$78.5 million in 2021, then decreased by 23.67% to -$97.0 million in 2022, then increased by 6.27% to -$91.0 million in 2023, then soared by 97.56% to -$2.2 million in 2024.